What are the side effects of enclomiphene?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 31, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Side Effects of Enclomiphene

Enclomiphene demonstrates a favorable safety profile with significantly fewer adverse effects compared to clomiphene citrate, though it shares the same FDA-labeled side effects as its parent compound. 1

Common Side Effects

Based on FDA labeling for clomiphene citrate (which enclomiphene is derived from), the following adverse effects may occur:

Visual Disturbances

  • Visual blurring, spots, flashes, or scotomata
  • Abnormal accommodation, eye pain
  • Macular edema, optic neuritis, photopsia
  • Retinal hemorrhage, retinal thrombosis, retinal vascular spasm
  • Posterior vitreous detachment
  • Temporary or prolonged loss of vision, possibly irreversible 1

Reproductive/Endocrine Effects

  • Ovarian/testicular enlargement
  • Pelvic or abdominal pain
  • Hot flashes (vasomotor flushes)
  • Reduced endometrial thickness
  • Gynecomastia (in males)

Gastrointestinal

  • Nausea and vomiting
  • Pancreatitis
  • Transaminases elevation, hepatitis

Metabolic

  • Hypertriglyceridemia (potentially leading to pancreatitis)
  • Elevated desmosterol levels with prolonged therapy 1

Psychiatric/Neurological

  • Mood changes, irritability, anxiety
  • Psychosis (rare)
  • Headache

Musculoskeletal

  • Arthralgia, back pain, myalgia

Comparative Safety Profile

Recent evidence demonstrates that enclomiphene has significantly fewer adverse effects than clomiphene citrate. A 2024 study of 66 patients showed enclomiphene was associated with:

  • Decreased libido (P=0.001)
  • Reduced energy (P=0.044)
  • Mood changes (P=0.03)

All occurred at statistically significantly lower rates compared to clomiphene, with an odds ratio of 0.18 (95% CI: 0.07-0.44, P=0.02) for adverse events 2. This represents an 82% reduction in adverse event risk compared to clomiphene.

Serious but Rare Adverse Events

The FDA label includes postmarketing reports of:

Neoplasms (Rare)

  • Ovarian cancer risk with prolonged use
  • Hepatic tumors (hepatocellular carcinoma, liver cell adenoma)
  • Various other malignancies (breast, endometrial, CNS tumors) 1

Congenital Abnormalities (if pregnancy occurs during treatment)

  • Neural tube defects
  • Cardiac malformations
  • Skeletal abnormalities
  • Genitourinary abnormalities 1

Hematologic

  • Leukocytosis
  • Elevated hematocrit (particularly relevant in male patients)

Clinical Pitfalls to Avoid

  1. Visual symptoms require immediate discontinuation - any visual disturbances warrant stopping the medication and ophthalmologic evaluation
  2. Monitor hematocrit in men - testosterone elevation can increase erythrocytosis risk
  3. Avoid in fertility planning - though enclomiphene preserves spermatogenesis better than testosterone, the Endocrine Society guideline notes that neither efficacy nor safety has been demonstrated in randomized trials for clomiphene compounds in hypogonadotropic hypogonadism 3
  4. Long-term use concerns - FDA recommends against cyclic therapy beyond approximately six cycles due to potential ovarian cancer risk (though this is primarily female data) 1

Metabolic Benefits

Notably, enclomiphene has shown unanticipated favorable effects on fasting plasma glucose 4, and a 2024 study demonstrated lower estradiol changes with enclomiphene (-5.92 pg/mL) compared to clomiphene (+17.50 pg/mL, P=0.001) 2, which may contribute to its improved tolerability profile.

References

2
Research

Safety and efficacy of enclomiphene and clomiphene for hypogonadal men.

Translational andrology and urology, 2024

3
Guideline

testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2018

Related Questions

How do I start enclomiphene (trans‑isomer of clomiphene) at 12.5 mg daily and what laboratory monitoring is required?
What are the recommended dosing directions and monitoring guidelines for enclomiphene?
What laboratory tests should be ordered and what next steps should be taken for a patient on enclomiphene who reports minimal symptom improvement and wants labs rechecked?
Is enclomiphene a selective estrogen receptor modulator (SERM)?
Would replacing enclomiphene citrate with tamoxifen be worthwhile for an adult male with secondary hypogonadism?
What diffusing capacity of the lung for carbon monoxide (DLCO) level is considered concerning in a patient on amiodarone?
Do patients with schizophrenia in the United States experience a higher proportion of violent auditory hallucinations compared to patients in other countries?
What are the differential diagnoses for a patient with elevated thyroid‑stimulating hormone (TSH) and low free thyroxine (free T4)?
Which viral infections cause oral ulcerations in pediatric patients?
What is an arterial thromboembolic event?
What does a low total iron‑binding capacity (TIBC), low unsaturated iron‑binding capacity (UIBC), and elevated ferritin indicate, and what is the appropriate management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.